Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2011 2
2012 8
2013 4
2014 10
2015 17
2016 7
2017 3
2019 2
2021 1
2022 1
2023 1
2024 1
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would lower the incidence of cardiovascular events is uncertain. ...The primary efficacy end point was a composite of nonfatal myocardial i …
BACKGROUND: High triglyceride levels are associated with increased cardiovascular risk, but whether reductions in these levels would …
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation.
Doshi SK, Kar S, Nair DG, Waggoner T, Agarwal H, Moussavian M, Kashani A, Oza S, Feldman L, Sadhu A, DeLurgio D, Alli O, Nielsen-Kudsk JE, Yamamoto M, Alkhouli M, Camm AJ, Coylewright M, Gibson CM, Granger CB, Gurol ME, Huber KC, Mansour M, Natale A, Pocock SJ, Reddy VY, Saliba WI, Asch FM, Wehrenberg S, Frost K, Christen T, Sutton BS, Stein KM, Leon MB, Ellenbogen KA; CHAMPION-AF Investigators. Doshi SK, et al. Among authors: alli o. N Engl J Med. 2026 Jun 4;394(21):2083-2094. doi: 10.1056/NEJMoa2517213. Epub 2026 Mar 28. N Engl J Med. 2026. PMID: 41910347 Clinical Trial.
The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for noninferiority (noninferiority margin, 4.8 percentage points) after 3 years of follow-up. ...CONCLUSIONS: Among patients with atrial fibrillation …
The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for nonin …
Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.
Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, Price MJ, Singh G, Schwartz JG, Kapadia S, Alli O, Horr S, Seshiah P, Batchelor W, Jones BM, Ahmed MI, Benza R, Jorde U, Thourani VH, Ghobrial AA, Tang GHL, Trusty PM, Huang D, Hahn RT, Adams DH, Sorajja P; TRILUMINATE Pivotal Investigators. Kar S, et al. Among authors: alli o. Circulation. 2025 Jun 10;151(23):1630-1638. doi: 10.1161/CIRCULATIONAHA.125.074536. Epub 2025 Mar 30. Circulation. 2025. PMID: 40159089 Free article. Clinical Trial.
BACKGROUND: One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid …
BACKGROUND: One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspi …
Percutaneous transcatheter valve replacement in individuals with mitral regurgitation unsuitable for surgery or transcatheter edge-to-edge repair: a prospective, multicountry, single-arm trial.
Guerrero ME, Daniels DV, Makkar RR, Thourani VH, Asch FM, Pham M, Muhammad KI, Greenbaum AB, Vasquez A, Oldemeyer JB, Dahle TG, Rihal C, Morse MA, Rodriguez E, O'Neill BP, Russo M, Whisenant B, Yadav P, Yu X, Wang DD, Makar M, Baran DA, Mahoney P, Reddy G, Blanke P, Webb J; ENCIRCLE Trial Executive Committee and Study Investigators. Guerrero ME, et al. Lancet. 2025 Nov 29;406(10519):2541-2550. doi: 10.1016/S0140-6736(25)02073-2. Epub 2025 Oct 27. Lancet. 2025. PMID: 41167201 Clinical Trial.
INTERPRETATION: Percutaneous transseptal TMVR with the SAPIEN M3 system effectively reduced mitral regurgitation with low rates of complications and mortality. These findings support percutaneous TMVR with the SAPIEN M3 system as a therapeutic option for patients wh …
INTERPRETATION: Percutaneous transseptal TMVR with the SAPIEN M3 system effectively reduced mitral regurgitation with low rates of co …
TAVR: Imaging Spectrum of Complications.
Singh SP, Alli O, Melby S, Lessar M, Sasse M, Booker J, Davies J. Singh SP, et al. Among authors: alli o. J Thorac Imaging. 2015 Nov;30(6):359-77. doi: 10.1097/RTI.0000000000000175. J Thorac Imaging. 2015. PMID: 26488207 Review.
Coronary artery fistulae.
Reddy G, Davies JE, Holmes DR, Schaff HV, Singh SP, Alli OO. Reddy G, et al. Among authors: alli oo. Circ Cardiovasc Interv. 2015 Nov;8(11):e003062. doi: 10.1161/CIRCINTERVENTIONS.115.003062. Circ Cardiovasc Interv. 2015. PMID: 26510560 No abstract available.
Left atrial appendage occlusion.
Alli O, Holmes D Jr. Alli O, et al. Heart. 2015 Jun;101(11):834-41. doi: 10.1136/heartjnl-2014-306255. Epub 2014 Dec 17. Heart. 2015. PMID: 25518846 Review.
Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic …
Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a signi …
Republished: Left atrial appendage occlusion.
Alli O, Holmes D Jr. Alli O, et al. Postgrad Med J. 2015 Sep;91(1079):527-34. doi: 10.1136/postgradmedj-2014-306255rep. Postgrad Med J. 2015. PMID: 26338996 Review.
Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a significant advancement in the field of cardiovascular disease. Prevention and avoidance of the devastating consequences of thromboembolic …
Left atrial appendage (LAA) occlusion for stroke and thromboembolism prevention in patients with atrial fibrillation (AF) represents a signi …
Aortic Valve Stenosis Treatment Disparities in the Underserved: JACC Council Perspectives.
Batchelor W, Anwaruddin S, Ross L, Alli O, Young MN, Horne A, Cestoni A, Welt F, Mehran R. Batchelor W, et al. Among authors: alli o. J Am Coll Cardiol. 2019 Nov 5;74(18):2313-2321. doi: 10.1016/j.jacc.2019.08.1035. J Am Coll Cardiol. 2019. PMID: 31672188 Free article. Review.
The reasons for these treatment gaps include differences in disease prevalence and patient, health care system, and disease-related factors. This has major implications not only for minority patients, but also for other groups who face similar challenges in accessing state …
The reasons for these treatment gaps include differences in disease prevalence and patient, health care system, and disease-related f …
54 results